|
|
 |
|
Viewing report
|
|
|
|
The Convergence of Biomarkers and Diagnostics: Therapy area analyses, key products and future trends
Business Insights, April 2008, Pages: 265
Business Insight's New Report Findings: Biomarkers are being developed to identify a disease and/or determine its course (biomarkers of disease), evaluate response to therapy (biomarkers of response), or predict individual susceptibility to disease or drug effects (biomarkers of susceptibility). In new drug development, when the biomarker or combination of biomarkers can be shown to be the single best measure of new drug's efficacy, a companion diagnostic is born. The drug-companion diagnostic combination is increasingly seen as a high value item.
Customers who bought this item also bought
Biomarkers - Technologies, Markets and Companies
Biomarkers 2008
Companion Biomarkers in Drug Development
Advances in Biomarkers
Blood Biomarkers and Beyond: Biomarker and Diagnostic Opportunities in Cardiovascular Disease
Biomarkers: The Future of Next-Generation Drug R&D
Cancer, CNS & Cardiovascular Biomarkers: Players, Products and Prospects
Biomarkers - Advanced Technologies and Global Market (2009-2014)
Cardiovascular Biomarkers: Players, Products and Prospects (Volume III)
Cancer Biomarkers: Players, Products and Prospects (Volume I)
Alzheimer's Disease Biomarkers, 2009
Trends in the Commercialization of Biomarkers: Tests and Companies
|
|
|
|
